CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype ...

What's especially promising is that MariTide can help people lose up to 20% of their body weight after a year, per a recent phase 2 trial. While analysts were hoping to see weight loss of up to 25 ...

Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections. But MariTide, which is Amgen's GLP-1 drug, only needs to be ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

The results also make MariTide the first obesity treatment with monthly or less frequent dosing to show effective weight loss in a phase 2 study, according to the company. Despite that assessment ...

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

"Physically, I feel stronger and healthier, but I do regret not focusing on muscle-building sooner," told Sara Conde, 22.